VINEETLAB36.00

Vineet Laboratories Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMMANGALAMLASAKREBSBIOALPABALPHARMAORTINGLOBENATCAPSUQMcap ₹69.2 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
VINEETLAB
FY26
BIOFILCHEM
FY26
MANGALAM
FY26
LASA
FY26
Peer
Median
Valuation — at last close
P/E36.00×21.05×21.05× +71%
P/B1.52×2.72×0.54×0.69×0.69× +120%
EV/EBITDA11.53×94.77×-10.74×-1.54×-1.54× +851%
Market Cap₹69.2 Cr₹58.6 Cr₹55.2 Cr₹34.2 Cr₹55.2 Cr +25%
Growth
Revenue CAGR 3Y-34.59%-1.85%-42.11%-21.98% -57%
Revenue CAGR 5Y-24.58%-4.50%-34.11%-19.30% -27%
Net Income CAGR 3Y8.59%70.67%70.67% -88%
Revenue YoY (latest Q)34.21%91.99%-0.40%-93.87%-0.40% +8653%
Net Income YoY (latest Q)111.58%-95.47%44.64%83.05%44.64% +150%
Profitability
EBITDA Margin14.27%2.29%-6.42%-112.98%-6.42% +322%
Net Income Margin2.70%9.81%-19.13%-135.60%-19.13% +114%
Return on Common Equity3.52%12.92%-43.08%-68.70%-43.08% +108%
Return on Capital Employed10.55%1.70%-27.98%-69.54%-27.98% +138%
Return on Assets1.29%6.50%-14.10%-51.44%-14.10% +109%
Credit & Quality
Total Debt/Equity0.99×0.14×1.02×0.20×0.20× +395%
Interest Coverage1.24×37.37×-2.04×-89.13×-2.04× +161%
Scale — latest FY
Revenue / Total Income₹59.4 Cr₹28.4 Cr₹232 Cr₹25.1 Cr₹28.4 Cr +109%
Net Income₹1.6 Cr₹2.8 Cr−₹44.4 Cr−₹34.1 Cr−₹34.1 Cr +105%
Total Assets₹125 Cr₹42.8 Cr₹315 Cr₹66.3 Cr₹66.3 Cr +88%
EPS₹1₹1.71₹-28.05₹-6.8₹-6.8 +115%
Book Value per Share₹23.74₹13.25₹65.11₹9.9₹13.25 +79%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.